tiprankstipranks
In this article:
Blurbs

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), AbbVie (ABBV)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALTResearch Report), AbbVie (ABBVResearch Report) and Meiragtx Holdings (MGTXResearch Report) with bullish sentiments.

Altimmune (ALT)

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Altimmune, with a price target of $25.00. The company’s shares closed last Monday at $4.72, close to its 52-week low of $4.34.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 5.3% and a 39.5% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $26.17, a 482.9% upside from current levels. In a report issued on April 28, B.Riley Financial also maintained a Buy rating on the stock with a $21.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AbbVie (ABBV)

In a report released yesterday, Joshua Schimmer from Evercore ISI maintained a Buy rating on AbbVie, with a price target of $153.00. The company’s shares closed last Monday at $147.87.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 5.4% and a 47.1% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $163.67, representing an 11.6% upside. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $180.00 price target.

Meiragtx Holdings (MGTX)

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Meiragtx Holdings. The company’s shares closed last Monday at $10.34, close to its 52-week low of $10.25.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 26.3% and a 38.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Meiragtx Holdings with a $30.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed